Results 111 to 120 of about 461 (138)
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy
JACC: Heart FailureÖzlem Bilen +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
New England Journal of MedicineBeta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that reduces left ventricular outflow tract gradients, improves exercise capacity, and decreases HCM symptoms when added to standard medications.
Michael E Nassif +2 more
exaly +3 more sources
Aficamten in the treatment of obstructive hypertrophic cardiomyopathy
Future CardiologyAficamten is a novel cardiac myosin inhibitor that has completed a Phase III trial for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Aficamten was developed to optimize pharmacokinetic properties and clinical tolerability relative to its predecessor, mavacamten.
Danish, Saleh +2 more
openaire +2 more sources
Aficamten in Hypertrophic Cardiomyopathy
Journal of the American College of Cardiologyexaly +2 more sources
Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten
Current Problems in CardiologyHypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), which can lead to left ventricular outflow tract (LVOT) obstruction. Traditional treatments often provide limited symptom relief and may not adequately reduce the LVOT gradient.
VÍCTOR Oluwatomiwa Ajekiigbe +2 more
exaly +3 more sources
XenobioticaAficamten, a small molecule selective inhibitor of cardiac myosin, was characterised in preclinical in vitro and in vivo studies.Protein binding in human plasma was 10.4% unbound and ranged from 1.6% to 24.9% unbound across species. Blood-to-plasma ratios ranged from 0.69 to 1.14 across species.
Donghong Xu
exaly +3 more sources
Aficamten in Non-Obstructive Hypertrophic Cardiomyopathy: Unlocking New Horizons?
European Journal of Heart FailureN ...
Rossi, Maddalena +2 more
openaire +3 more sources
Aficamten for Obstructive Hypertrophic Cardiomyopathy
New England Journal of MedicineJorge, Pedreira-Bouzas +2 more
openaire +3 more sources
Aficamten Monotherapy for Hypertrophic Cardiomyopathy
New England Journal of MedicineMapelli, Massimo +2 more
openaire +4 more sources